GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » EBITDA Margin %

VANI (Vivani Medical) EBITDA Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vivani Medical's EBITDA for the three months ended in Sep. 2024 was $-6.20 Mil. Vivani Medical's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Vivani Medical's EBITDA margin for the quarter that ended in Sep. 2024 was 0.00%.


Vivani Medical EBITDA Margin % Historical Data

The historical data trend for Vivani Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical EBITDA Margin % Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
- - - -

Vivani Medical Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vivani Medical's EBITDA Margin %

For the Biotechnology subindustry, Vivani Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivani Medical's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Vivani Medical's EBITDA Margin % falls into.


;
;

Vivani Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Vivani Medical's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-26.608/0
= %

Vivani Medical's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-6.197/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivani Medical  (NAS:VANI) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Vivani Medical EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Vivani Medical's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivani Medical Business Description

Traded in Other Exchanges
Address
1350 S. Loop Road, Alameda, CA, USA, 94502
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division.
Executives
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck 10 percent owner 33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer director
Patrick Ryan officer: Chief Operating Officer C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342